ストックスクリーナーアプリを入手
9.66
1.15%
0.11
プレマーケット:
9.83
0.17
+1.76%
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as chief medical officer - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz
Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer - marketscreener.com
Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals names Leonardo Nicacio as CMO - Investing.com
Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan
Corbus adds new medical chief ahead of CRB-701 cancer study - Stock Titan
Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Risk Channels and Responsive Allocation - Stock Traders Daily
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2000 Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark - marketscreener.com
CRBP Q1 2026 Earnings: EPS Beats Estimates Amid Pipeline ProgressAnalyst Consensus Shift - dars.gov.et
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000E Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2500 Index - marketscreener.com
CRBP Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Price to sales forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – BOATS:CRBP - TradingView
Corbus Pharmaceuticals (CRBP) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
CRBP Maintained by Mizuho -- Price Target Lowered to $34 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $34 - Moomoo
Corbus Pharmaceuticals Holdings Inc (CRBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
(CRBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRBP News | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Corbus Pharmaceuticals Sharesanalyst consensus snapshot - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $52 - Moomoo
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 By Investing.com - Investing.com Nigeria
Oppenheimer cuts Corbus Pharmaceuticals stock price target to $52 - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Stock (US21833E1038): Nasdaq price action in focus on a quiet news day - Ad-hoc-news.de
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
CRBP Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid No RevenueEarnings Manipulation Risk - dars.gov.et
Corbus Pharmaceuticals teases cancer, obesity data as key clinical readouts near - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near - Yahoo Finance
1.48%
0.70%
大文字化:
|
ボリューム (24 時間):